Form 4: Centessa Pharmaceuticals CEO Exercises Options and Sells Shares Under Pre-Arranged Trading Plan

Centessa Pharmaceuticals plc CEO Saurabh Saha exercised stock options and subsequently sold 55,000 ordinary shares for approximately $12.63 per share, as part of a pre-established 10b5-1 trading plan.

Summary

• Saurabh Saha, Chief Executive Officer and Director of Centessa Pharmaceuticals plc, executed a transaction on June 20, 2025, involving the company's Ordinary Shares.
• He acquired 55,000 Ordinary Shares by exercising share options at a price of $3.85 per share.
• Concurrently, Mr. Saha sold 55,000 Ordinary Shares at a weighted average price of $12.6332 per share, with individual sales ranging from $12.50 to $12.80.
• These sales were conducted pursuant to a Rule 10b5-1 trading plan, which was adopted on May 16, 2024.
• Following these transactions, Mr. Saha directly holds 221,017 Ordinary Shares and indirectly holds 38,000 Ordinary Shares through a trust.
• He also retains 205,000 unexercised share options with an exercise price of $3.85, which vest in monthly installments, with the first installment vesting on March 1, 2023, and an expiration date of February 1, 2033.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While it involves insider selling, the transaction was pre-planned under a 10b5-1 plan, mitigating concerns about opportunistic trading. The CEO also realized a significant gain on the exercised options, which is a positive for the individual.

Positives

• The exercise of options at $3.85 and subsequent sale at an average of $12.6332 indicates a significant profit for the CEO on these specific shares, demonstrating value realization from his compensation.
• The transaction was conducted under a Rule 10b5-1 trading plan, which suggests the sale was pre-scheduled and not based on immediate, non-public information, enhancing transparency and reducing concerns about opportunistic insider trading.

Negatives

• Insider selling, even under a 10b5-1 plan, can sometimes be perceived negatively by some investors as it reduces the insider's direct equity stake in the company.

Risks

• While the document itself does not explicitly list risks, the sale of shares by a key executive, even if pre-planned, could be interpreted by some investors as a potential signal, though this is largely mitigated by the existence of the 10b5-1 plan.

Future Outlook

The document, an SEC Form 4, details an insider transaction and does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This filing reports a routine insider transaction by a key executive, which is a common occurrence across all industries. It does not provide specific insights into broader industry trends or competitive dynamics, but rather reflects an individual's compensation and personal financial planning.

Related Party Transactions

• 38,000 Ordinary Shares are held indirectly by a trust, for which the Reporting Person (Saurabh Saha) and his spouse serve as trustees.

Stakeholder Impact

• Shareholders: May view the insider sale with slight caution, though the pre-arranged 10b5-1 plan largely mitigates concerns about the timing or motivation of the sale. The CEO's continued significant direct and indirect holdings, along with unexercised options, still align his interests with shareholders.

Key Dates

Recommendation

Keywords

Centessa Pharmaceuticals, CNTA, Saurabh Saha, SEC Form 4, Insider Trading, Stock Option Exercise, Share Sale, 10b5-1 Plan, Executive Compensation, Beneficial Ownership